Avista Public Acquisition Corp. II
AHPA
NASDAQ Capital Market6.13
USD
-0.71
- -
Avista Public Acquisition Corp. II
AHPA
(NASDAQ Capital Market)
Recent
price
6.13
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Avista Public Acquisition Corp. II (AHPA) operates as a blank check special purpose acquisition company (SPAC) sponsored by Avista Capital Partners, focusing on mergers, share exchanges, asset acquisitions, or similar business combinations primarily in the healthcare, technology, and sustainability sectors; it targets high-growth companies with enterprise values between $500 million and $1.5 billion. Formed in 2020 and headquartered in New York, New York, the company completed its initial public offering in August 2021, raising $230 million through the sale of 23 million units at $10 each, with proceeds held in trust for a de-SPAC transaction. AHPA does not conduct substantive operations prior to completing an initial business combination and invests trust proceeds in U.S. government securities, money market funds, or similar low-risk instruments. In a major strategic development completed on November 1, 2022, AHPA merged with OmniAb, Inc., a subsidiary of Ligand Pharmaceuticals Incorporated, in a reverse Morris Trust transaction structured as a tax-free spin-off; this deal provided the combined entity with up to $266 million in gross cash proceeds, assuming minimal redemptions, and resulted in OmniAb emerging as an independent public company listed on Nasdaq under the ticker OABI, with former AHPA shareholders retaining exposure through the post-merger structure. The business combination, approved by AHPA shareholders on October 24, 2022, followed a definitive merger agreement announced on March 23, 2022, and supported by up to $115 million in commitments from Avista Capital Partners, including a PIPE investment and redemption backstop. As of 2025, AHPA's Class A ordinary shares (NASDAQ: AHPA), units (AHPAU), and warrants (AHPAW) reflect a closed SPAC status post-de-SPAC, with the ticker noted as potentially delisted or inactive amid ongoing market tracking of legacy securities.
OmniAb Announces Completion of Spin-Off and Business Combination
Ligand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI™ (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
OmniAb Business Combination Approved by APAC Shareholders
Ligand Announces Record Date and Details for Distribution for OmniAb Spin-Off
Ligand Reports Second Quarter 2022 Financial Results